Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors

A compound of Formula (I):

• or a pharmaceutically acceptable salt,
• wherein:
• X1 is C;
• X2 is S or NR6;
• X3 is N or CR7, wherein, one of X2 or X3 is N;
• R1 is OH;
• R2 is (C1-C6) alkyl, (C6-C14) aryl, (C3-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R8;
• R4 is (C1-C6) alkyl or (C6-C14) aryl, wherein the aryl is optionally substituted with one or more R12;
• R5 and R5′ are independently H;
• R6 is H;
• R7 is H;
• each R8 is independently (C1-C6) alkyl, halogen, —(C0-C4)-alkylene-aryl, —(C0-C4)-alkylene-heteroaryl, —(C0-C4)-alkylene-O-heteroaryl, or —C(O)R19, wherein the alkyl, alkylene, aryl, and heteroaryl are optionally substituted with one or more R9;
• each R9 is independently (C1-C6) alkyl, halogen, or —NR21S(O)qR22;
• each R12 is independently (C6-C14) aryl, heteroaryl, —O—(C3-C8)cycloalkyl, or halogen, wherein the aryl and cycloalkyl are optionally substituted with one or more R13;
• each R13 is halogen;
• each R19 is (C2-C6) alkenyl;
• each R21 and R22 is independently H or (C2-C6) alkenyl;
• m is 0;
• n is 1;
• and
• q is 2.